AF / 1635 PTO/SB/21 (09-04) MODIFIED DFV

	DE	Application Number: 09/998,009				
TRANSMITTAL	LE 2	Filing Date:	November 28, 2001			
5004	אר אחר	First Named Inventor:	Mari	Marina Konopleva		
FORM NUG	5 8 mm &	Art Unit:	1635			
\3.		Examiner Name: R. Cook				
Total Number of Pages in this Submitted in August 1		Attorney Docket Number:	UTSC:652US			
ENCLOSURES (check all that apply)						
Fee Transmittal Form	Dr Dr	awings(s)		After Allowa	nce Communication to TC	
Fee Attached						
Amendment/Reply	Lic	ensing-related Papers		Appeal Communication to Board of Appeals and Interferences		
After Final	Per	tition				
Affidavits/declaration(s)	Per	tition to Convert to a Provisional		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
1 —		pplication wer of Attorney, Revocation,				
—				Proprietary Information		
		nange of Correspondence		Status Letter		
Information Disclosure		Statement under 37 CFR §3.73(b)		Other Enclosure(s) (please identify below)  Check in the amount of \$		
Statement		Designation of Patent Practitioners				
Form PTO-1449				Authorized to be charged to deposit account		
References		Terminal Disclaimer if check insufficient or inadvertently Deposit account number: 50-1212/L				
Certified Copy of Priority Documents		Request for Refund		Sequence Statement		
		CD, Number CD(s)		Paper Copy of Sequence Listing		
Reply to Missing Parts/		Landscape Table on CD		Computer Readable Form (CRF)  Postcard		
Incomplete Application		Declaration Under 37 C.F.R.		n Under 37 C F D &1 132		
Reply to Missing Parts/Requirements		Declaration Onder 37 C.F		11 Olider 37 C.P.R. §1.132		
Declaration(s)				LJ		
Copy of Notice of Missing						
Parts/Requirements	-					
	Remai	Remarks:				
SAGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
	//	CE OF APPLICANT, ATTOR				
Firm Name Fulbright & Jawe	dy Mi, L.L.P.		-   (	Customer Number	32425	
Signature						
Printed Name   Steven L. High	lander	Reg. No. 37,642				
Date August 23, 2005						
	CERT	IFICATE OF TRANSMISSIO	N/M	AILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissionet per Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature						
Typed or Printed Name	ghlander		Date A	august 23, 2005		
	\					



## CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below:

August 23, 2005

Date

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marina Konopleva et al.

Group Art Unit:

Steven L. Highlander

1635

Serial No.: 09/998,009

Examiner:

R. Cook

Filed: November 28, 2001

Atty. Dkt. No.: UTSC:652US/SLH

For: CDDO-COMPOUNDS AND

COMBINATION THERAPIES THEREOF

## **DECLARATION UNDER 37 C.F.R. §1.132**

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

We, the undersigned, do declare that:

- We are the named inventors of the above-captioned application. 1.
- We are the authors of Konopleva et al., Blood 96(11) Part 1, pp.121a, 2000. Also listed 2. as authors on that abstract were Irina Stiouf, Zeev Estrov, Twee Tsao, David Harris, Mark Munsell, Clinton Leysath, Shourong Zhao, Ellen C. Jackson, and Shi-rong Chang.

-1-25563712.1

3. The contributions for each of these individuals is set forth below:

**Irina Stiouf** was a post-doctoral fellow who developed several flow cytometry assays utilized in this study by the inventors.

Zeev Estrov was a co-director of the tissue culture core in the AML-PO1 grant who directed clonogenic assays upon request of the inventors.

Twee Tsao was a technical assistant (Senior Research Assistant in Dr. Andreeff's laboratory) who performed protein analysis as directed by the inventors.

**David Harris** was a technical assistant (Research Assistant in Dr. Estrov's laboratory) who performed clonogenic assays as directed by the inventors.

Mark Munsell provided statistical analysis for publication.

Clinton Leysath was a technical assistant (Research Assistant in Dr. Andreeff's laboratory) who conducted tissue culture and flow cytometry experiments under supervision of the inventors.

Shourong Zhao was an instructor who provided expertise in Western blot analysis and PCR.

Ellen C. Jackson was a Research Nurse who provided clinical information about AML samples were used.

**Shi-rong Chang** was a technical assistant (Research Assistant in Dr. Andreeff's laboratory) who validated conditions for Western blot analysis of several proteins utilized by the inventors in the current study.

4. Thus, these individuals did not contribute conceptually to the subject matter of the above-captioned application, and thus were properly not listed as inventors thereon.

25563712.1 -2-

5. We hereby declare that all statements made herein of our knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

8/10/2005	Key-
Date	Marina Konopleva, MD, PhD
Date	Michael Sporn, MD
8/14/05	1
Date	Michael Andreeff/MD. PhD